Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency

FDA approved avatrombopag for thrombocytopenia in CLD patients scheduled for a procedure

/1 Comment/in /by

 

You might also like
FDA approved lutetium Lu 177 dotatate for the treatment of somatostatin receptor-positive GEP-NETs
Glasdegib plus low-dose cytarabine (LDAC) approved in elderly AML patients
FDA approved nilotinib for paediatric patients with newly diagnosed Ph+ CML-CP or Ph+ CML-CP resistant or intolerant to prior TKI
FDA granted regular approval to olaparib in the treatment of (suspected) deleterious germline BRCA-mutated, HER2-negative MBC
Lorlatinib FDA approved for metastatic ALK-positive NSCLC
FDA approved enzalutamide (XTANDI, Astellas Pharma US, Inc.), for patients with castration-resistant prostate cancer (CRPC). More Information.  July 13, 2018 Filgrastim-aafi FDA approved as Filgrastim Biosimilar
PARPi talazoparib FDA approved for deleterious gBRCAm HER2‑negative breast cancer
Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency FDA approves venetoclax in 2nd-line for patients with CLL or SLL
1 reply

Trackbacks & Pingbacks

  1. FDA approved avatrombopag for thrombocytopenia in CLD patient scheduled for a procedure - MediNews Asia says:
    23rd May 2018 at 11:47 PM

    […] post FDA approved avatrombopag for thrombocytopenia in CLD patient scheduled for a procedure appeared first on Medical Writer Agency | 香港醫學作家 | MediPR | MediPaper Hong […]

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply